Search Options Stock News and Analysis from Schaeffer's

https://www.schaeffersresearch.com/content/bgs/2022/01/07/the-worst-stock-to-buy-this-january

1/7/2022 10:23 AM

As we say welcome in the New Year with cautious optimism, it’s important to note not just the best stock picks to bet on, but also the ones to avoid. Historically, there are a notable amount of names ...

Special Report: Avoid These Two Healthcare Stocks

https://www.schaeffersresearch.com/content/analysis/2021/10/12/special-report-avoid-these-two-healthcare-stocks

10/12/2021 3:04 PM

Last month was a doozy for investors. We've discussed how investors can manage September seasonality ad nauseam, but what about the other side of the coin? What stocks out there could fall victim to ...

Inflation Fears, Funding Stalemate Cap Off September Slide

https://www.schaeffersresearch.com/content/news/2021/10/01/inflation-fears-funding-stalemate-cap-off-september-slide

10/1/2021 3:01 PM

If you're an investor, you're probably sick of the words 'September seasonality' by now. As the historically bearish period came to a close and ushered in a new month, all eyes were on Congress and ...

AbbVie Stock Rises After FDA Approves 3rd Headache Drug

https://www.schaeffersresearch.com/content/news/2021/09/29/abbvie-stock-rises-after-fda-approves-3rd-headache-drug

9/29/2021 10:02 AM

The U.S. Food and Drug Administration (FDA) just approved AbbVie Inc's (NYSE:ABBV) migraine prevention treatment, marking the company's third drug in its roster for severe headaches. The once-daily o...

AbbVie Stock Inching Toward Highs Amid Drug Sale Talks

https://www.schaeffersresearch.com/content/news/2021/03/16/abbvie-stock-inching-toward-highs-amid-drug-sale-talks

3/16/2021 10:19 AM

AbbVie Inc (NYSE:ABBV) is in the spotlight this morning, after news that the pharmaceutical company is in talks to sell a $5 billion portfolio of women's drugs. According to Reuters, the company acqui...

PEOPLE ALSO SEARCH FOR

-intraday-options-activity